Maintenance therapy with olaparib or selumetinib plus durvalumab (S+D) according to genetic profile of metastatic pancreatic adenocarcinoma (m-PDAC) controlled with modified FOLFIRINOX (mFFX): A phase II randomized MAZEPPA GERCOR D19-02 PRODIGE-72 study

ANNÉE

2024

AUTEURS

Hammel P, Ben Abdelghani M, Roth G, Ulusakarya A, Ghiringhelli F, Toullec C, Borg C, Hentic Dhome O, Trouilloud I,Dahan L, Hiret S, Bouche O, Rinaldi Y, Blanc JF, De La Fouchardiere C, Neuzillet C, Kamal M, Falcoz A, Turpin A, Guimbaud R

CONGRÈS/REVUE

ASCO GI

ÉTUDE

Localisation

LIEN PUBLICATIONS ASSOCIÉES